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ABSTRACT Live-attenuated Listeria monocytogenes has shown encouraging poten-
tial as an immunotherapy platform in preclinical and clinical settings. However, addi-
tional safety measures will enable application across malignant and infectious dis-
eases. Here, we describe a new vaccine platform, termed Lm-RIID (L. monocytogenes
recombinase-induced intracellular death), that induces the deletion of genes required
for bacterial viability yet maintains potent T cell responses to encoded antigens. Lm-RIID
grows normally in broth but commits suicide inside host cells by inducing Cre re-
combinase and deleting essential genes ﬂanked by loxP sites, resulting in a self-
limiting infection even in immunocompromised mice. Lm-RIID vaccination of mice
induces potent CD8 T cells and protects against virulent challenges, similar to live
L. monocytogenes vaccines. When combined with -PD-1, Lm-RIID is as effective as
live-attenuated L. monocytogenes in a therapeutic tumor model. This impressive efﬁ-
cacy, together with the increased clearance rate, makes Lm-RIID ideal for prophylac-
tic immunization against diseases that require T cells for protection.
KEYWORDS Listeria monocytogenes, biotechnology, cell-mediated immunity,
immunotherapy, vaccines
Listeria monocytogenes is a Gram-positive intracellular pathogen that induces innateand adaptive immune responses in mice, enabling long-lived protection against
itself (1) or viral (2, 3) or parasitic (4) challenge and therapeutic beneﬁt in mouse tumor
models (3, 5–10). Protection depends on CD8 T cells (1, 2, 8, 11, 12), and, together with
other advantages, such as straightforward manufacturing and the ability to repeatedly
administer L. monocytogenes (7), has paved the way for clinical trials in advanced
cancers (13–15). Key to the clinical advancement of L. monocytogenes vaccines has been
the development of genetically deﬁned live-attenuated vaccines that retain the immu-
nologic potency of wild-type (WT) strains. However, with safety a paramount require-
ment for broad applicability, we have sought additional approaches to prevent patho-
genesis while retaining the capacity to prime potent T cell immunity.
L. monocytogenes vaccine attenuation has been achieved through different strate-
gies. A common approach involves virulence or metabolic gene deletion. Deletion of
actA, which encodes a protein that mediates cell-to-cell spread, results in a strain that
is 1,000-fold less virulent than WT L. monocytogenes in mice yet is capable of inducing
protective immunity (5, 11). L. monocytogenes can also be attenuated through deletion
of the gene encoding the virulence regulator PrfA, which is partially complemented
when expressed from a plasmid. Both approaches have yielded vaccines with accept-
able safety proﬁles in patients with advanced cancer (13, 14, 16).
An alternative attenuation strategy is engineering vaccines that cannot replicate in
host cells. One example is an L. monocytogenes vaccine that undergoes lysis in host cells
to facilitate DNA, RNA, and/or protein delivery (17–20). These strains rely on a bacte-
riophage lysin that is expressed only when L. monocytogenes reaches the host cytosol.
Citation Hanson WG, Benanti EL, Lemmens EE,
Liu W, Skoble J, Leong ML, Rae CS, Fassò M,
Brockstedt DG, Chen C, Portnoy DA, Dubensky
TW, Jr, Lauer P. 2019. A potent and effective
suicidal Listeria vaccine platform. Infect Immun
87:e00144-19. https://doi.org/10.1128/IAI
.00144-19.
Editor Nancy E. Freitag, University of Illinois at
Chicago
Copyright © 2019 Hanson et al. This is an
open-access article distributed under the terms
of the Creative Commons Attribution 4.0
International license.
Address correspondence to Peter Lauer,
peter.mi.lauer@gmail.com.
* Present address: William G. Hanson, Actym
Therapeutics, Berkeley, California, USA; Justin
Skoble, Actym Therapeutics, Berkeley,
California, USA; Chris S. Rae, Actym
Therapeutics, Berkeley, California, USA; Marcella
Fassò, Genentech, Inc., South San Francisco,
California, USA; Dirk G. Brockstedt, FLX Bio, Inc.,
South San Francisco, California, USA; Chen
Chen, Elem Biotech, Wuhan, China; Thomas W.
Dubensky, Jr., Tempest Therapeutics, San
Francisco, California, USA.
W.G.H. and E.L.B. contributed equally to the
manuscript.
Received 18 February 2019
Returned for modiﬁcation 27 March 2019
Accepted 24 May 2019
Accepted manuscript posted online 24
June 2019
Published
MICROBIAL IMMUNITY AND VACCINES
crossm
August 2019 Volume 87 Issue 8 e00144-19 iai.asm.org 1Infection and Immunity
23 July 2019
Another example is KBMA (for killed but metabolically active) vaccines that consist of
bacteria rendered sensitive to long-wavelength UV light by deletion of uvrAB, genes
required for nucleotide excision repair (3). Low-level photochemical cross-linking of
bacterial DNA renders KBMA bacteria unable to replicate, yet they access host cytosol
and prime CD8 T cells, leading to therapeutic beneﬁts in a mouse tumor model. L.
monocytogenes also has been attenuated by the deletion of genes required for syn-
thesis of the cell wall component D-alanine (21). These strains require D-Ala for growth
in vitro and to generate functional immune responses in mice yet do not replicate
inside host cells. All three of these attenuation strategies are less potent than live L.
monocytogenes (3, 6, 20–22), which is consistent with lysis in host cells being detri-
mental to immunogenicity (23).
Live-attenuated double-deleted L. monocytogenes (LADD) vaccines are being eval-
uated for the treatment of advanced-stage cancer. These vaccines are deleted for actA
and inlB (5), a membrane-localized internalin required for hepatocyte invasion (24), and
are cleared from mice by 4 days postimmunization yet induce robust immune re-
sponses similar to those of WT L. monocytogenes. Although LADD vaccines have been
safely administered to more than 450 late-stage cancer patients (Aduro Biotech, Inc.,
unpublished data), further enhancing LADD vaccine safety could allow for its use in an
even broader population (e.g., early-stage cancers and chronic infectious diseases).
The requirement for L. monocytogenes to be alive (replication competent) to induce
potent immune responses presents a challenge in balancing attenuation while main-
taining sufﬁcient viability for vaccine potency. LADD vaccines induce immune re-
sponses due to their ability to enter and grow in the host cell cytosol, activate innate
immunity, and express exogenous antigens that are processed and presented by host
cells. However, it is unknown how long viability is required after antigen expression,
and a loss in viability at later times postimmunization may increase vaccine safety. Here,
we describe a new genetic strategy that leads to L. monocytogenes suicide in host cells.
These strains, termed Lm-RIID for Listeria monocytogenes recombinase-induced intra-
cellular death, excise essential genes upon entering the host cell cytosol. In mice,
Lm-RIID strains are cleared faster than LADD strains from the liver and spleen yet induce
similar immune responses, provide protective immunity against homologous (virulent)
L. monocytogenes or heterologous vaccinia challenge, and confer therapeutic efﬁcacy in
a mouse tumor model. Combining Lm-RIID with -PD-1 therapy increased survival to
100%, the same efﬁcacy as that of LADD. The enhanced safety properties and robust
potency make Lm-RIID an attractive alternative to existing vaccines.
RESULTS
Lm-RIID construction and growth. To construct a vaccine with short-term viability
that is still capable of robust antigen expression, we developed a suicidal L. monocy-
togenes strain that deletes essential genes upon reaching the intracellular milieu.
Initially, LADD (ΔactA ΔinlB strains) was engineered with lox sites ﬂanking three sets of
genes including or adjacent to the replication origin (Fig. 1a; see also Fig. S1 in the
supplemental material). The Cre recombinase gene was inserted at the actA locus under
the control of the actA promoter, which is not expressed in broth but induced when L.
monocytogenes reaches the host cytosol (25).
Genes near or encompassing the replication origin are essential due to roles in DNA
replication, repair, and recombination (26–28). To test whether gene excision decreases
viability, growth of ﬂoxed L. monocytogenes strains with or without Cre was compared
in broth and during infection of murine dendritic-like DC2.4 cells. Strains with (e.g.,
BH3618) or without (e.g., BH3210) Cre grew identically in broth (Fig. S2a, c, and e). While
strains without Cre increased CFU by two logs in DC2.4 cells over 7 h, Cre L.
monocytogenes CFU decreased by four logs (Fig. S2b, d, and f). These data demonstrate
that suicidal L. monocytogenes loses viability following infection of host cells, likely as
a result of the deletion of essential genes.
Gene excision by suicidal L. monocytogenes. We hypothesized that Cre induc-
tion leads to excision of ﬂoxed genes, resulting in bacteria unable to replicate their
Hanson et al. Infection and Immunity
August 2019 Volume 87 Issue 8 e00144-19 iai.asm.org 2
DNA. To measure excision, we focused on BH3618 that contains ﬂoxed yaaA, recF, gyrB,
and gyrA (here referred to as Lm-RIID, for Listeria monocytogenes recombinase-induced
intracellular death). Strains with a ﬂoxed origin (29, 30) formed chains inside cells, which
generally correlates with poor immunogenicity (P. Lauer, unpublished observations), so
FIG 1 Suicidal L. monocytogenes (Lm-RIID) undergoes intracellular chromosomal excision. (a) Schematic overview of
genomic alterations and cassettes in one L. monocytogenes suicide vaccine strain, including the following four
components: (i) deletion of virulence genes actA and inlB; (ii) lox sites ﬂanking essential genes; (iii) inducible PactA-cre
at the actA locus; (iv) vaccine antigen cassette integrated at inlB, tRNAArg, or comK loci. (b) Primer pairs were designed
to amplify the native conﬁguration of the gyrase region (primers 1 and 2) and the Cre-mediated excision product
(primers 1 and 3). DC2.4 cells were infected with LADD or Lm-RIID, and infected cell lysates at 0, 3, or 16 h postinfection
were used as templates for PCRs with primers 1 and 2 (native, N) or primers 3 and 4 (excised, E). White lines on the
PCR gel indicate where lanes were digitally rearranged to group data by LADD and Lm-RIID platforms.
An Effective Suicidal Listeria Vaccine Platform Infection and Immunity
August 2019 Volume 87 Issue 8 e00144-19 iai.asm.org 3
these were not pursued further. LADD and Lm-RIID were used to infect DC2.4 cells, and
PCR was performed to distinguish between the intact yaaA-recF-gyrB-gyrA locus and the
excised DNA product (Fig. 1b). The excision product was detected soon after Lm-RIID
infection, increased over time, and inversely correlated with native product levels. In
contrast, LADD samples exclusively contained the native product throughout the
infection. These results demonstrate that Lm-RIID excises essential genes after access-
ing host cytosol, consistent with decreased CFU numbers in DC2.4 cells.
Lm-RIID loses intracellular activity by 9 hpi. Numbers of bacterial CFU following
infection were reduced as early as 3 h postinfection (hpi). However, when growth was
monitored by microscopy, LADD and Lm-RIID numbers were similar, at least up to 5 hpi
(Fig. S3a and b). These results were surprising, as Lm-RIID CFU clearly decreased
compared with those of LADD. Importantly, CFU enumeration requires further rounds
of replication for colony formation while imaging captures replication directly.
To investigate the functional capabilities of Lm-RIID, we used a plaque assay, which
measures growth and cell-to-cell spread and requires 3 days and multiple infection
cycles to occur. Because plaque formation requires ActA, actA was integrated site
speciﬁcally at the comK locus of Lm-RIID (31). ActA expression was similar following
infection with WT L. monocytogenes, an actA deletion strain (LmΔactA::pPL1-actA strain),
or an Lm-RIID strain complemented at the comK locus (Lm-RIID::pPL1-actA strain) (Fig.
2a, lanes 3 to 5), and ActA strains formed actin tails in host cells (Fig. 2b). Three days
following infection, WT and LmΔactA::pPL1-actA strains formed plaques but Lm-RIID
did not, consistent with the presence of ActA and actin tail formation in the ﬁrst two
strains (Fig. 2c). Importantly, the Lm-RIID::pPL1-actA strain was unable to form plaques
despite its ability to form actin tails. These data demonstrate that although growth of
Lm-RIID cells is visible by microscopy at 5 hpi and they form actin tails at 6 hpi, they are
unable to spread in a cell monolayer over 3 days of infection.
To more precisely determine when Lm-RIID bacteria are affected by chromosomal
excision, cell-to-cell spread was measured by an infectious focus assay (32). Importantly,
growth of L. monocytogenes strains in A549 cells was similar to that in DC2.4 cells (Fig.
S3c). WT L. monocytogenes cells form foci of 24 host cells per focus (HC/F) at 6 hpi, and
these grow to 120 HC/F by 12 hpi (Fig. S4). LmΔactA::pPL1-actA cells form foci of size
similar to that of WT L. monocytogenes (Fig. 2d and Fig. S4). In contrast, Lm-RIID::pPL1-
actA foci plateau at 34 HC/F at 9 hpi with no further increase in size, demonstrating that
Lm-RIID cells stop spreading at this time (Fig. 2d and e).
Accelerated clearance of Lm-RIID in WT and immunocompromised mice. Viable
Lm-RIID was not recoverable from host cells at 7 hpi. However, whether this strain
replicated in animals was unknown. To measure replication in vivo, CD-1 mice were
vaccinated intravenously (i.v.) with LADD or Lm-RIID, and CFU in spleen and liver were
enumerated over time. Lm-RIID was cleared faster than LADD, with no detectable CFU
by day 1 in spleen and day 2 in liver (Fig. 3a and b). LADD was not cleared until 4 days
postvaccination, consistent with previous observations (5). We hypothesized that in
vivo clearance of Lm-RIID should be independent of the host immune status. To test
this idea, clearance was measured in CD-1 nude mice that lack T cells. LADD clearance
in nude mice took longer than that of WT mice (28 versus 4 days in spleen; Fig. 3c and
d). In contrast, Lm-RIID was cleared with similar kinetics in nude and WT mice,
demonstrating that Lm-RIID organisms drive their own accelerated clearance indepen-
dent of the host.
Decreased virulence of Lm-RIID::pPL1-actA strain. The increased clearance rate
suggests Lm-RIID is less virulent than LADD. To determine whether Lm-RIID virulence
is reduced, median lethality (i.e., LD50) was measured in mice (Table S2). LADD itself is
highly attenuated, and Lm-RIID displayed a similarly high level of attenuation (LD50,
1 108) compared to that of WT L. monocytogenes (1 105). Cre expression alone did
not further attenuate LADD (strain BH3099, LD50 of 1 108). However, complemen-
tation with actA revealed an additional level of attenuation for Lm-RIID that would not
be appreciated from the strain lacking actA due to an upper limit of 1 108 for LD50
Hanson et al. Infection and Immunity
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measurements. While LADD complemented for actA (LADD::pPL1-actA strain) exhibited
an LD50 identical to that of WT L. monocytogenes (1 105), the LD50 of the Lm-RIID::
pPL1-actA strain was 3 logs less (LD50 of 1 108).
Lm-RIID induces a robust immune response. Although accelerated clearance and
reduced virulence may increase vaccine safety, these changes may also impact immuno-
genicity. To test the potency of Lm-RIID, we compared immunogenicity to LADD and KBMA
FIG 2 Lm-RIID stops spreading from cell to cell at 9 h postinfection. (a) Intracellular Western blot of infected cell lysates from 8-h DC2.4
infections. A polyclonal antibody speciﬁc to the mature amino terminus of the ActA protein was used to detect ActA and ActA fusion
proteins. Lanes 1 and 2, empty vector negative controls of LADD and Lm-RIID; 3 to 5, WT L. monocytogenes, Lm-act::pPL1-actA, and
Lm-RIID::pPL1-actA strains; 6, OVA in LADD; 7 and 8, AH1/A5-OVA fusion protein in LADD and Lm-RIID; 9 and 10, QuadVac fusion protein
in KBMA and Lm-RIID platforms. (b) Fluorescence images of actin tails formed by WT, Lm-act::pPL1-actA, Lm-RIID, and Lm-RIID::pPL1-actA
strains. L. monocytogenes organisms were stained with -L. monocytogenes O-antigen antibody (red), host actin ﬁlaments with Alexa
Fluor-488 phalloidin (green), and DNA with DAPI (blue). Scale bar, 5 m. (c) Representative images of plaque assays with L2 cells at 72 h
postinfection. (d) Fluorescence images of infectious foci formed by Lm-act::pPL1-actA and Lm-RIID::pPL1-actA strains in A549 cells. L.
monocytogenes organisms were stained with -L. monocytogenes O-antigen antibody (red), host cell membranes with --catenin
antibody (green), and DNA with DAPI (blue). Scale bar, 100 m. (e) The number of host cells per infectious focus following infection of
A549 cells with the Lm-act::pPL1-actA or Lm-RIID::pPL1-actA strain. Asterisks denote Lm-RIID::pPL1-actA foci signiﬁcantly different from
Lm-act::pPL1-actA foci (*, P 0.1; **, P 0.0001; both by two-way analysis of variance [ANOVA]).
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strains (3). KBMA is a version of LADD that is inactivated by cross-linking DNA, which
prevents replication. To measure immune responses, an antigen expression cassette com-
posed of 4 vaccinia CD8 epitopes as well as the OVA257–264 epitope (SIINFEKL; the entire
cassette was termed QuadVac) was integrated at the inlB locus of Lm-RIID, KBMA (6), and
LADD strains (Fig. 1a). QuadVac was expressed at similar levels from Lm-RIID and KBMA
platforms following DC2.4 infection (Fig. 2a, lanes 9 and 10). Enzyme-linked immunosor-
bent spot (ELISPOT) assay measurement of splenocytes 7 days postimmunization revealed
that KBMA elicited 4- to 7-fold-reduced immune responses, whereas Lm-RIID induced
responses that were either similar to (C4L125–132 and LLO296–304) or modestly reduced
(1.2-fold decrease for B8R20–27 and OVA257–264 and 2- to 2.5-fold decrease for A42R88–96
and K3L6–15) relative to those of LADD (Fig. 4). These results indicate that Lm-RIIDmaintains
the ability to induce robust responses to foreign antigens.
Lm-RIID provides protective immunity in bacterial and viral challenge models.
A hallmark of L. monocytogenes immunity is the induction of life-long protection against
virulent L. monocytogenes challenge after a single vaccination, a measure of priming
functional T cells. To determine if Lm-RIID can protect against a lethal L. monocytogenes
challenge, mice were immunized with LADD, KBMA, or Lm-RIID and challenged 6weeks
later with twice the LD50 of WT L. monocytogenes. Lm-RIID provided 5 logs of protection,
nearly the level of LADD (6 logs of protection; Fig. 5a), while KBMA provided 1 log of
protection. To assess immune response quality in a heterologous virulence challenge, mice
were vaccinated twice with each QuadVac-expressing strain and then challenged with
vaccinia virus. In this model, KBMA provided just 1 log of protection, while both LADD and
Lm-RIID provided greater than 3 logs of protection (Fig. 5b), indicating that Lm-RIID
protects against bacterial and viral challenge, similar to LADD.
Lm-RIID confers therapeutic efﬁcacy in a tumor challenge model. To evaluate
efﬁcacy in a therapeutic CT26 lung metastasis model (Fig. 6a), LADD and Lm-RIID were
engineered to express the T cell epitope AH1-A5 from the tumor rejection antigen gp70
(33, 34) fused to ovalbumin (OVA) (LADD-AH1-A5-OVA and Lm-RIID-AH1-A5-OVA). Both
strains expressed similar levels of AH1-A5-OVA protein (Fig. 2a, lanes 7 and 8). LADD
expressing OVA alone was used as a negative control (LADD-OVA). LADD-AH1-A5-OVA
prolongs survival in this model compared to Hank’s balanced salt solution (HBSS) and
LADD-OVA controls (P 0.0001) (5). Lm-RIID-AH1-A5-vaccinated mice also exhibited
FIG 3 Lm-RIID is cleared from WT and immunocompromised mice faster than LADD. WT (a and b) or CD-1 nude
(nu/nu) (c and d) mice were vaccinated i.v. with 5 106 CFU of LADD (open circles) or Lm-RIID (solid circles). After
vaccination (30 min, 4 h, and 1, 2, 4, 7, 14, 22, and 28 days), spleens and livers were homogenized, dilutions were
plated on BHI medium, and CFU per organ were enumerated. LOD, limit of detection.
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prolongation of life, with 50% long-term survivors (Fig. 6b), demonstrating that Lm-RIID
displays signiﬁcant therapeutic efﬁcacy in this model.
Combination therapy with Lm-RIID and -PD-1 is as effective as LADD treat-
ment. The checkpoint inhibitor antibody -programmed cell death 1 (-PD-1) mediates
profound clinical responses in patients with cancer (35), particularly in malignancies
with high mutational burden (36). -PD-1 treatment reinvigorates CD8 T cells by
blocking inhibitory signaling, although one prerequisite for checkpoint therapy respon-
FIG 4 Lm-RIID induces robust immune responses to heterologous vaccinia virus antigen. C57BL/6 mice were
injected (5 106 CFU) i.v. twice 5 weeks apart with LADD, KBMA, or Lm-RIID containing an antigen expression
cassette that includes four vaccinia CD8 T cell epitopes and the OVA257–264 (SIINFEKL) epitope. Splenic T cell
responses were measured by IFN- ELISPOT assay. Unstimulated responses (open circles) and stimulated
responses (gray circles) are shown for A42R (a), C4L (b), K3L (c), B8R (d), OVA257–264 (e), and LLO296–304 (f). The
L. monocytogenes-speciﬁc CD8 T cell epitope LLO296–304 served as a positive control. Signiﬁcance was
calculated using a two-way ANOVA: ***, P 0.0001; ns, not signiﬁcant.
FIG 5 Lm-RIID vaccination protects against virulent WT L. monocytogenes and vaccinia virus challenge. (a) C57BL/6
mice were vaccinated once with a LADD, KBMA, or Lm-RIID strain that expresses the QuadVac cassette. Mice were
challenged 6 weeks later with twice the median lethal dose (LD50) of WT L. monocytogenes. (b) C57BL/6 mice were
vaccinated twice 30 days apart with a LADD, KBMA, or Lm-RIID QuadVac strain. Mice were challenged 7 weeks later
with WT vaccinia virus. Five days after challenge, PFU were enumerated from ovaries of infected mice. Signiﬁcance
was determined using a Student’s t test: *, P 0.05; **, P 0.01.
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siveness is an inﬂamed tumor microenvironment (TME) (37). Checkpoint therapy could
synergize with treatments that induce T cell responses and inﬂame the TME, such as
LADD vaccination (12, 14, 15). To test this idea, LADD, Lm-RIID, and -PD-1 were tested
in the CT26 lung metastasis model, similar to the monotherapy experiment, but with or
without -PD-1 (Fig. 6a and c). Monotherapies resulted in low (1/8 survivor, -PD-1) or
modest (3/8 survivors, Lm-RIID) survival beneﬁt (Fig. 6d). However, the combination of
Lm-RIID and -PD-1 increased survival to 100%, the same as that seen for LADD
monotherapy. These data indicate that Lm-RIID synergizes with checkpoint inhibition
to cure CT26 lung metastases and demonstrate that Lm-RIID can be as efﬁcacious as
LADD for cancer treatment.
DISCUSSION
Effective vaccinology requires a delicate balance between safety (attenuation) and
immune potency. Diverse approaches have been developed among recombinant
bacterial and viral platforms that prevent pathogenicity but preserve the capacity to
target antigen-presenting cells, activate innate immunity, and present antigens on
FIG 6 Lm-RIID is partially effective alone and fully effective in combination with PD1 checkpoint
blockade at curing mice with CT26 lung metastases. (a) Schematic of the CT26 lung metastasis model
and L. monocytogenes treatment regimen. (b) BALB/c mice were challenged i.v. with 2 105 CT26
tumor cells and vaccinated 4 and 18 days later with 5 106 CFU of LADD-OVA, LADD-AH1/A5-OVA,
or Lm-RIID-AH1/A5-OVA and then monitored for survival. (c) Schematic of the CT26 lung metastasis
model and L. monocytogenes and -PD1 treatment regimen. IP, intraperitoneal. (d) BALB/c mice were
challenged i.v. with 2 105 CT26 tumor cells and vaccinated 3 days later with 5 106 CFU of
LADD-OVA, LADD-AH1/A5-OVA, or Lm-RIID-AH1/A5-OVA. Two additional groups vaccinated with
LADD-AH1/A5-OVA or Lm-RIID-AH1/A5-OVA also received -PD1 (200 g) on days 3, 7, and 10
postimplantation. Survival is plotted for each group, and groups are identiﬁed in the panel.
Hanson et al. Infection and Immunity
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major histocompatibility complex class I and class II molecules. The ideal vaccine strain
would be that which is the most highly attenuated yet elicits the strongest functional
immune responses. We have previously described the development of the LADD
platform, which has been tested extensively in patients with diverse malignancies (5,
14, 15). Here, we describe Lm-RIID, which contains an additional layer of safety through
a genetic program that catalyzes its own destruction following antigen expression and
presentation.
Lm-RIID is more attenuated than LADD, as evidenced by its increased clearance rate
from mice and an increased LD50 in an actA background. Furthermore, the nearly
irreversible nature of Cre with mutant lox sites (38) in Lm-RIID ensures that reversion
is highly unlikely. Therefore, Lm-RIID is an attractive alternative to LADD. Although
Lm-RIID induced immune responses similar to those of LADD for some epitopes, other
responses were reduced as much as 2.5-fold, indicating that the higher degree of
attenuation dampens immunogenicity. Despite this reduction, Lm-RIID protects ani-
mals against L. monocytogenes and vaccinia challenges, demonstrating that its immu-
nogenicity is sufﬁcient for protection. The antitumor efﬁcacy of Lm-RIID with -PD1
further indicates that Lm-RIID is potent enough to generate effective responses. The
quality of CD8 T cells is also a key factor in driving effective immune responses, and
additional experiments are required to determine whether the quality of T cells induced
by Lm-RIID and LADD differs. Furthermore, how these preclinical results will translate to
humans remains to be determined.
Excision of essential genes reduces Lm-RIID viability in host cells, which is apparent
by 3 hpi when measuring CFU. However, direct observations by microscopy indicated
that Lm-RIID organisms continue to divide at least through 5 hpi. Measuring infectious
foci of ActA strains revealed that Lm-RIID stops spreading around 9 hpi. This is
consistent with measurements of protein expression, which were similar for LADD and
Lm-RIID at 8 hpi. A delay in the loss of Lm-RIID viability is not surprising and may reﬂect
bacteria that have undergone chromosomal excision yet maintain YaaA, RecF, GyrB,
and/or GyrA activity prior to death, presumably as these essential proteins are diluted
by replication. Increasing the half-life of one or more of these proteins could extend
Lm-RIID survival.
KBMA is an attenuated version of LADD that is defective for replication under any
condition (3). uvrAB deletion prevents cross-link repair yet allows for metabolic activity
and escape from the phagolysosome following host cell invasion. ActA KBMA recruits
host actin but cannot undergo actin-based motility, an effect that was observed as early
as 5 hpi, earlier than when Lm-RIID stops spreading at 9 hpi. Consistent with an earlier
growth defect, KBMA had a greater reduction in immunogenicity than Lm-RIID (5-
versus 2.5-fold), suggesting that the longer duration of growth is necessary for maxi-
mum immune responses. Further Lm-RIID modiﬁcation or, as discussed below, com-
bining Lm-RIID with other immunotherapies may boost responses.
Lm-RIID and KBMA are similarly efﬁcacious as monotherapies in mouse tumor
models (40 to 50% survival for both). Checkpoint inhibition has not been tested with
KBMA, raising the question of whether this would similarly enhance efﬁcacy. Studies
examining the effect of checkpoint inhibition on LADD immune responses suggest that
-PD1 treatment prolongs the activation of LADD-induced cytotoxic T cells (W. Deng,
unpublished data). Other immunomodulatory therapies, such as -CTLA4, -OX40, and
-GITR, also synergize with LADD in preclinical models (39 and M. Leong, C. Rae, and
W. Deng, unpublished data), and the effect of these on Lm-RIID efﬁcacy will be
important to evaluate as well. The ability of different immunomodulatory antibodies to
alter Lm-RIID responses could reveal keys to the mechanism of action of this vaccine.
A common strategy for attenuation of live bacterial vaccines is through inhibition of
intracellular replication. Some notable examples include a Salmonella enterica serotype
Typhi galE mutant, which takes up galactose for cell wall incorporation that enables
immunogenicity and protection but also leads to the accumulation of toxic levels of
galactose metabolites (40). Francisella novicida strains were engineered to express
psychrophilic essential genes (41). These strains displayed temperature-sensitive (ts)
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growth, with normal growth at 30 to 35°C but no growth in host cells at 37°C, and they
elicited protective immunity in mice. Lm-RIID is similar to these ts strains in that
essential proteins are depleted to eliminate vaccine following antigen expression;
however, it takes advantage of genetic removal of genes rather than ts proteins. The
Lm-RIID strategy may enable a longer half-life, which could enhance antigen delivery
and immune responses.
L. monocytogenes vaccines have shown promising results both preclinically and in
clinical trials, yet there are limitations on which patients can be treated with attenuated
L. monocytogenes. Lm-RIID represents an important step toward the development of L.
monocytogenes vaccines that can be administered to a broader population of patients
and used for the prophylactic treatment of infectious diseases. The synergy of Lm-RIID
with checkpoint inhibition is particularly promising in light of the expanding use of
checkpoint therapy and suggests an obvious immunotherapy combination to explore
further.
MATERIALS AND METHODS
Bacterial strain construction. Strains used in this study are listed in Table S1 in the supplemental
material. Allelic exchange (including deletions and lox, frt, Cre, FLP, and antigen expression cassette
insertions) was performed with oriT-containing derivatives of pKSV7 as previously described (31, 42).
Site-speciﬁc integration at comK and tRNAArg was performed with the pPL1 and pPL2 integration vectors
as previously described (31). The Cre and FLP recombinase coding sequences were optimized for Listeria
expression, synthesized (ATUM, Newark, CA), and cloned immediately downstream of the actA promoter.
For direct comparisons to KBMA, some suicidal strains were constructed in the KBMA background to
allow for photochemical inactivation with S-59 (3). Complementation of ActA was achieved with pPL25
as previously described (31). The QuadVac expression cassette expresses four CD8 T cell epitopes fused
to the amino terminus of ActA (6). The gp70 epitope strains AH1 (WT; SPSYVYHQF) and AH1/A5 (APL;
SPSYAYHQF) were based on a previously described ActA-(epitope)-OVA fusion strategy (43) and were
constructed by epitope site-speciﬁc integration at tRNAArg with pPL2. Strains were veriﬁed by PCR
analysis and sequencing.
In vitro growth curves. Overnight brain heart infusion (BHI) cultures were diluted 1:100, aliquoted
(150 l per well) into a 96-well, ﬂat-bottom plate, and monitored for growth using a VersaMax microplate
reader (Molecular Devices, Sunnyvale, CA).
Intracellular growth curves. Murine dendritic DC2.4 cells (44) were maintained in RPMI 1640
(Thermo Fisher Scientiﬁc, Waltham, MA) supplemented with 10% heat-inactivated fetal bovine serum
(FBS; HyClone, GE Healthcare, Pittsburgh, PA), 23.8 mM sodium bicarbonate (Sigma, Saint Louis, MO),
1 nonessential amino acids (Cellgro; Corning, Tewksbury, MA), 2 mM L-glutamine (Cellgro), 10 mM
HEPES buffer (Gibco), 1 mM sodium pyruvate (Sigma), and 50 M -mercaptoethanol (Sigma).
Human lung carcinoma A549 cells (ATCC, Manassas, VA) were maintained in Ham’s F-12K medium
(Gibco) with 10% heat-inactivated FBS (HyClone). Growth curves in both cell types were performed
in 24-well tissue culture plates (Costar 3524; Corning, NY). For DC2.4 studies, cells (2 105) were
seeded in each well and infected at a multiplicity of infection (MOI) of 20. For A549 studies, cells
(1.5 105) were seeded in each well and infected at an MOI of 50. L. monocytogenes strains were
grown overnight in BHI at 30°C without agitation and then diluted into cell culture media such that
the total CFU for the desired MOI was in a 0.5-ml volume. Cells were infected for 1 h and washed
with 1 ml phosphate-buffered saline (PBS; HyClone), and then cell culture medium containing
gentamicin (50 g/ml) was added to prevent growth of extracellular bacteria. Bacteria were har-
vested at increasing times postinfection by aspirating the media, washing cell monolayers (1 ml PBS),
and lysing the cell monolayer hypotonically with sterile water (1 ml). Serial dilutions were plated on
BHI agar plates supplemented with streptomycin (200 g/ml; Teknova, Hollister, CA) and incubated
overnight at 37°C, and colonies were counted to determine the number of CFU/well. Each strain was
measured in triplicate, and the means with the standard deviations are reported.
PCR chromosomal excision assay. DC2.4 cells (1 106) were seeded in 12-well tissue culture plates
and incubated overnight. The following day, cells were infected at an MOI of 25 for 1 h and rinsed twice
with PBS, and then cell culture medium containing gentamicin (60 g/ml) was added. Infected lysates
were harvested at increasing times postinfection by aspirating culture media, rinsing once with PBS, and
lysing cells in water by repeated pipetting and scraping. Three wells for each strain and time point were
pooled, PBS was added to a ﬁnal concentration of 1, and genomic DNA was isolated using a MasterPure
Gram-positive DNA puriﬁcation kit (Epicentre, Middleton, WI) according to the manufacturer’s instruc-
tions. PCRs using genomic DNA as the template and combinations of primer 1 (TCGTAATCGTGGTGGT
ATGGGT), primer 2 (AAAACTACTGCTATAAACAGA), and primer 3 (TCCACCAGTTGAAACTACATCA) were
performed with Phusion polymerase (NEB, Ipswich, MA) on a Bio-Rad T100 thermal cycler (Hercules, CA).
Intracellular Western blotting. DC2.4 cells (3 105) were seeded in each well of a 12-well tissue
culture plate and incubated overnight. Cells were infected at an MOI of 10 for 1 h and rinsed with PBS,
and RPMI complete medium containing 50 g/ml gentamicin was added. Cells were cultured seven
additional hours before washing with PBS (1 ml) and lysing cells in 1 lithium dodecyl sulfate (LDS)
buffer (150 l of a mix of 4 LDS buffer [Life Technologies, Grand Island NY], Tris-EDTA buffer [Fisher
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Scientiﬁc], and sample reducing agent [Life Technologies]). Cell lysates were incubated at 95°C for
10 min, and aliquots (20 l) were run on 4 to 12% Bis-Tris PAGE gels in 1 morpholineethanesulfonic
acid buffer (Invitrogen) and transferred to nitrocellulose membranes for detection. Membranes were
blocked for 1 h in Odyssey blocking buffer (Li-Cor, Lincoln, NE), and heterologous antigens were detected
with a polyclonal rabbit antibody (1:4,000) that recognizes the mature 18-amino-acid N terminus of ActA.
Labeled goat anti-rabbit (IRDye 680RD; Odyssey) secondary antibody was used at a 1:10,000 dilution.
Antibodies were diluted in Odyssey blocking buffer with 0.2% Tween 20. Membranes were incubated
with primary antibody overnight at 4°C, washed three times for 5 min each wash with PBS containing
0.1% Tween, and then incubated with secondary antibody for 1 h at room temperature. Membranes were
washed a further four times, the last wash with PBS only, and then scanned using a Li-Cor Odyssey
system.
Fluorescence microscopy. For ﬁxed imaging of bacterial replication, actin tails, and infectious foci,
DC2.4 cells (2 105), Cos7 cells (5 104), or A549 cells (4.5 105) were seeded onto coverslips in 24-well
tissue culture plates and infected for 1 h. Cos7 and A549 infections included an initial centrifugation step
(200 g for 5 min). After 1 h, monolayers were washed with PBS (1 ml), cell culture medium with
gentamicin (50 g/ml) was added, and coverslips were ﬁxed with 4% formaldehyde (Polysciences) in PBS
for 10 min at the times indicated in the text. Cos7 cells were maintained in Dulbecco’s modiﬁed Eagle’s
medium (DMEM; Gibco) and A549 cells were maintained in Ham’s F-12K medium (Gibco), both with 10%
heat-inactivated FBS (HyClone). Immunoﬂuorescence staining was performed by ﬁrst permeabilizing and
blocking coverslips for 30 min at room temperature (2% bovine serum albumin [BSA] and 0.1% Triton
X-100 in PBS; BSA-PBSTX), followed by incubation with primary antibody(ies) for 30 min. Coverslips were
washed (3, PBS), incubated with secondary antibody(ies) for 30 min, washed again (3, PBS), and then
mounted onto glass slides with ProLong diamond antifade mountant (Life Technologies). All antibodies
were diluted in BSA-PBSTX. L. monocytogenes was detected using an -Listeria O antigen polyclonal
rabbit antibody (1:200; BD Biosciences, Franklin Lakes, NJ) and Alexa Fluor 594- or Alexa Fluor 488-
conjugated anti-rabbit secondary antibody (1:200; Invitrogen). Cells and actin were visualized by includ-
ing Alexa Fluor 488- or Alexa Fluor 594-conjugated phalloidin (1:250; Invitrogen) and 4=,6-diamidino-2-
phenylindole (DAPI) (Fisher Scientiﬁc) in the secondary antibody step. For A549 staining, cell membranes
were detected with an --catenin antibody (1:250; BD Biosciences) and an Alexa Fluor 488-conjugated
-mouse secondary antibody (1:250; Invitrogen).
Imaging was performed with an inverted Nikon TiE microscope, and images were captured with an
Andor Zyla sCMOS camera controlled by NIS Elements software (Nikon, Melville, NY). Bacterial replication
and actin tail images were taken with a 60 (1.4 numeric aperture [NA]) PlanApo objective and infectious
focus images with a 20 (0.5 NA) Plan Fluor objective. Image analysis was performed in Fiji (45, 46). For
microscopy measurements of intracellular bacterial replication, the number of bacteria in individual host
cells was counted using the Cell Counter plugin for ImageJ. For each strain and time point, infected host
cells in 10 ﬁelds of view (FOV) from two coverslips were counted for a minimum of 150 infected host cells
per strain and time point. For infectious focus analysis, the number of host cells per focus was counted
using the Cell Counter plugin for ImageJ, and a minimum of 12 infectious foci were analyzed for each
strain and time point.
Plaque assay. Plaque assays with murine L2 ﬁbroblasts were performed as previously described (47).
Brieﬂy, L2 cells (1.2 106) were seeded onto 6-well plates 1 day before infection. The next day, the
optical densities of static, overnight 30°C cultures of L. monocytogenes were normalized, and cultures
were washed three times in PBS and allowed to infect L2 monolayers for 1 h. Cells were washed three
times, overlaid with 3 ml of 0.7% agar containing 10 g/ml gentamicin, and incubated at 37°C. Three
days later a second overlay of 2 ml of 0.7% agar-gentamicin and 25 l neutral red (Sigma-Aldrich) was
added, plates were incubated overnight, and plaque size was analyzed using ImageJ (http://rsbweb.nih
.gov/ij/). At least three wells were analyzed per mutant per experiment.
Animals. C57BL/6, BALB/c, CD1, CD1nu/nu, and SCID beige mice were obtained from Charles River
Laboratories (Wilmington, MA). Mice were handled according to National Institutes of Health guidelines.
All animal protocols were approved by the Aduro Biotech Institutional Care and Use Committee. L.
monocytogenes vaccinations were given intravenously at the doses indicated in the text.
In vivo growth kinetics. CD1 or CD1nu/nu mice were immunized with the indicated L. monocytogenes
strains (5 106 CFU), and the level of infection in each mouse in the liver and spleen was determined
by isolating, homogenizing, diluting, and plating for CFU for each organ.
Median lethality (LD50). Median lethality experiments were performed as previously described (5).
Brieﬂy, C57BL/6 mice were immunized with the indicated L. monocytogenes strains at a dose equal to 0.1
LD50 and survival was monitored over time.
ELISPOT assay and peptides. ELISPOT assays were performed with lymphocytes isolated from
whole mouse blood using Lympholyte-mammal (Cedarlane Labs, Burlington, NC) and a murine gamma
interferon (IFN-) ELISPOT pair (BD Biosciences, San Jose, CA). Cells (2 105) were plated in anti-murine
IFN--coated ELISPOT plates (Millipore, Billerica, MA) and incubated overnight at 37°C with the indicated
peptides or without peptide as a negative control. A42R88–96 (YAPVSPIVI), C4L125–132 (LNFRFENV), K3L6–15
(YSLPNAGDVI), B8R20–27 (TSYKFESV) (48), OVA257–264 (SIINFEKL), and LLO190–201 (NEKYAQAYPNVS) pep-
tides were synthesized by Synthetic Biomolecules (San Diego, CA). Plates were developed using alkaline
phosphatase detection reagents (Invitrogen, Carlsbad, CA) and scanned and quantitated using an
ImmunoSpot plate reader and software (CTL Ltd., Cleveland, OH).
WT L. monocytogenes challenge. Female C57BL/6 mice were vaccinated once with 5 106 CFU of
each L. monocytogenes strain. Thirty-four days later, mice were challenged with 2 LD50 of the WT L.
monocytogenes strain DP-L4056 (31). Three days later, spleens and livers were harvested, homogenized,
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and diluted. Bacterial burden (CFU per organ) was determined by plating dilutions on BHI agar plates
containing 200 g/ml streptomycin.
Vaccinia challenge. Female C57BL/6 mice were vaccinated on day 0 and day 29 with 5 106 CFU
of each L. monocytogenes strain. Mice were challenged 49 days after the second vaccination with WT
vaccinia intraperitoneally (1 106 PFU). Ovaries were harvested 5 days postchallenge, and plaque assays
were performed to determine the level of protection (3).
Tumor studies. Female BALB/c mice were implanted intravenously (i.v.) on day 0 with the CT26
tumor cell line engineered to express human mesothelin (2 105). For monotherapy studies, mice were
vaccinated i.v. with L. monocytogenes strains (5 106 CFU) 4 days postimplantation and boosted with the
same dose 14 days later. For combination treatment studies, mice were vaccinated i.v. once with L.
monocytogenes strains (5 106 CFU) 3 days postimplantation. Combination groups also received intra-
peritoneal injections of -PD1 (200 g) on days 3, 7, and 10 postimplantation. HBSS was used as a
negative control for all studies. Mice were weighed and monitored daily and were euthanized upon any
signs of stress or labored breathing.
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